Axsome Therapeutics (AXSM) Q1 2025 Earnings
Axsome Therapeutics reported Q1 2025 revenue of $121.5M (+62.0% YoY), missed analyst consensus of $140.4M by $19.0M. Diluted EPS came in at $-0.80 (+26.6% YoY), beat the $-1.26 consensus by $0.46.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Axsome Therapeutics's Q1 2025 earnings report.
Axsome Therapeutics (AXSM) reported Q1 2025 earnings on May 5, 2025 before market open.
Axsome Therapeutics reported revenue of $121.5M and diluted EPS of $-0.80 for Q1 2025.
Revenue missed the consensus estimate of $140.4M by $19.0M. EPS beat the consensus estimate of $-1.26 by $0.46.
Compared to the same quarter a year prior, revenue grew 62.0% from $75.0M a year earlier and diluted EPS grew 26.6% from $-1.09.
You can read the 10-Q periodic report (0000950170-25-063634) directly on SEC EDGAR. The filing index links above go to sec.gov.